Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Expression and prognostic role of RhoA GTPases in hepatocellular carcinoma

  • 153 Accesses

  • 29 Citations

Abstract

The Rho sub-family of proteins is involved in regulating the organization of the cytoskeleton and in cell motility. Our aim is to clarify the clinical significance of Rho protein in hepatocellular carcinomas (HCC) and to determine the relationship between the level of expression and patient outcome following hepatectomy. The expression of RhoA protein in HCC and corresponding non-tumor tissues of 26 patients who underwent surgical resection was analyzed by immunoblotting. The expression level of each case was calculated as tumor/non-tumor (T/N) ratios. High expression (T/N≥1) of RhoA protein in HCC compared to the paired non-tumor tissues was recognized in 18 patients (69.2%) of 26 samples. The activity of RhoA is also increased in HCC with high expression of RhoA. The high expression of RhoA protein did not correlate with various clinical parameters. However, the disease-free survival rates of the RhoA-high expression group (T/N≥1) were significantly lower than those of the RhoA-low expression group (T/N<1) (P<0.05). The high expression of RhoA protein in HCC plays an important role in intrahepatic recurrence of patients who underwent a hepatectomy for HCC, and RhoA is a useful marker for predicting early recurrence in an early-stage HCC.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Adamson P, Marshall CJ, Hall A, Tilbrook PA (1992) Post-translational modifications of p21rho proteins. J Biol Chem 267:20033–20038

  2. Avraham H, Weinberg RA (1989) Characterization and expression of the human rhoH12 gene product. Mol Cell Biol 9:2058–2066

  3. Bourne HR, Sanders DA, McCormick F (1990) The GTPase superfamily: a conserved switch for diverse cell functions. Nature 348:125–132

  4. Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, Jin DY, Ng IO (2003) Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 278:10824–10830

  5. Fritz G, Just I, Kaina B (1999) Rho GTPases are over-expressed in human tumors. Int J Cancer 81:682–687

  6. Genda T, Sakamoto M, Ichida T, Asakura H, Kojiro M, Narumiya S, Hirohashi S (1999) Cell motility mediated by Rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology 30:1027–1036

  7. Hao J, Ju H, Zhao S, Junaid A, Scammell-LaFleur TK, Dixon IMC (1999) Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol 31:667–678

  8. Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, Watanabe G, Tsurumaru M (1993) Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 71:19–25

  9. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5:221–225

  10. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, Oshima H (2003) Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9:2632–2641

  11. Kawata S, Yamasaki E, Nagase T, Inui Y, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y (2001) Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84:886–891

  12. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M, Sassa T (1997) Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25:87–92

  13. Lang P, Guizani L, Vitte-Mony I, Stancou R, Dorseuil O, Gacon G, Bertoglio J (1992) ADP-ribosylation of the ras-related, GTP-binding protein RhoA inhibits lymphocyte-mediated cytotoxicity. J Biol Chem 267:11677–11680

  14. Leung TH, Ching YP, Yam JW, Wong CM, Yau TO, Jin DY, Ng IO (2005) Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci USA 102:15207–15212

  15. Machesky LM, Hall A (1996) Rho: a connection between membrane receptor signaling and the cytoskeleton. Trends Cell Biol 6:304–310

  16. Makuuchi M, Kosuge T, Takayasu T, Yamazaki S, Kakazu T, Miyagawa S, Kawasaki S (1993) Surgery for small liver cancers. Semin Surg Oncol 9:298–304

  17. Nakashima T (1976) Vascular changes and hemodynamics in hepatocellular carcinoma. In: Okuda K, Peter RL (eds) Hepatocellular carcinoma. Wiley, New York, pp 169–203

  18. Narumiya S, Morii N (1993) Rho gene products, botulinum C3 exoenzyme and cell adhesion. Cell Signal 5:9–19

  19. Perona R, Esteve P, Jimenez B, Ballestero RP, Ramon y Cajal S, Lacal JC (1993) Tumorigenic activity of rho genes from Aplysia californica. Oncogene 8:1285–1292

  20. Ren X, Kiosses WB, Schwartz MA (1999) Regulation of the small GTP-binding protein Rho by cell adhesion and cytoskeleton. EMBO J 18:578–585

  21. Sebti SM, Hamilton AD (1997) Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol Ther 74:103–114

  22. Simonetti RG, Camma C, Fiorello F, Politi F, D’Amico G, Pagliaro L (1991) Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 36:962–972

  23. Takaishi K, Sasaki T, Kotani H, Nishioka H, Takai Y (1997) Regulation of cell–cell adhesion by rac and rho small G proteins in MDCK cells. J Cell Biol 139:1047–1059

  24. Takamura M, Sakamoto M, Genda T, Ichida T, Asakura H, Hirohashi S (2001) Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 33:577–581

  25. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389:990–999

  26. Yoshioka K, Matumura F, Akedo H, Itoh K (1998) Small GTP-binding protein rho stimulates the actomyosin system, leading to invasion of tumor cells. J Biol Chem 276:5146–5154

  27. Yoshioka K, Nakamoto S, Itoh K (1999) Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res 59:2004–2010

  28. Zhang FL, Casey PJ (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65:241–269

Download references

Author information

Correspondence to Koji Fukui.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fukui, K., Tamura, S., Wada, A. et al. Expression and prognostic role of RhoA GTPases in hepatocellular carcinoma. J Cancer Res Clin Oncol 132, 627–633 (2006). https://doi.org/10.1007/s00432-006-0107-7

Download citation

Keywords

  • RhoA
  • Hepatocellular carcinoma
  • Recurrence